Women who participated in prolonged, frequent bicycling had decreased genital sensation and were more likely to have a history of genital pain than women runners, researchers in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine and The Albert Einstein College of Medicine report in the current issue of the Journal of Sexual Medicine.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that a single once-daily morning dose of the investigational amphetamine compound SPD465, extended release triple-bead mixed amphetamine salts, designed to reduce symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults for up to 16 hours, was bioequivalent to a dose of ADDERALL XR (mixed salts of a single-entity amphetamine product) followed by a dose of mixed amphetamine salts immediate release (“MAS IR”) eight hours later.
One in four U.S. adults say they suffered a day-long bout of pain in the past month, and one in 10 say the pain lasted a year or more, according to the government’s annual, comprehensive report of Americans’ health, Health United States, 2006, released today by the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics.
One in four U.S. adults say they suffered a day-long bout of pain in the past month, and one in 10 say the pain lasted a year or more, according to the government’s annual, comprehensive report of Americans’ health, Health United States, 2006, released today by the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics.
Amgen (NASDAQ: AMGN) announced patients with ankylosing spondylitis who received treatment with Enbrel (R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy, according to data from an ongoing open-label, multinational, phase 4 extension study presented at the American College of Rheumatology scientific meeting. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks.
Abbott and Kos Pharmaceuticals, Inc. today announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net of cash currently held by Kos. Based in Cranbury, N.J., Kos is a specialty pharmaceutical company that develops and markets proprietary medications for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company has a growing presence in the $20 billion lipid management market.
University of Manchester researchers are recruiting people with backache caused by nerve root pain — commonly known as sciatica — in the first ever study to discover if therapeutic ultrasound can help their condition.
A new capital fund of ?10 million to improve the provision of occupational health services to NHS staff and in turn increase the availability of NHS Plus, the network of NHS occupational health departments that provide occupational health services to small and medium sized enterprises, was announced by health minister Rosie Winterton today.
New plans for faster, better and more convenient care for the millions of people who suffer from bone and joint ailments such as arthritis, back pain and fractures were announced today by Health Minister Andy Burnham.
Lower back pain is one of the most common causes of job-related disability and why some people miss work. It is also the second most common neurological ailment in the United States, second only to headache. In fact, approximately 80% of adults in Western countries have, at some point, experienced lower back pain.